[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aron Research Foundation Ets\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100625301","international-multicentric-retrospective-study-on-the-use-of-evp-as-first-line-therapy-in-patients-with-lamuc-100625301",false,"NCT07420855","International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la\u002FmUC","International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced\u002FMetastatic Urothelial Cancer (ARON-2PLUS)","ARON-2PLUS","Inclusion Criteria:\n\n* Patients aged \\>18years\n* Histologically confirmed diagnosis of la\u002FmUC of upper and\u002For lower urinary tract or histologically confirmed diagnosis of rare GU tumors.\n* Histologically or radiologically confirmed metastatic disease\n* Patients treated with first-line EV+P combination\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of UC\n* Patients without histologically or radiologically confirmed la or mUC","ALL","18 Years",{"count":20,"type":21},361,"ESTIMATED","OBSERVATIONAL","The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced\u002Fmetastatic Urothelial Cancer.\n\nTwo supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.",[25,26],"Locally Advanced or Metastatic Urothelial Cancer","Urothelial Cancer",[28,29,30,31],"urothelial cancer","pembrolizumab","enfortumab vedotin","rare genitourinary tumors","NOT_YET_RECRUITING","2026-02-12",{"date":35,"type":36},"2026-02-19","ACTUAL",{"date":38,"type":21},"2026-02",{"date":40,"type":21},"2030-12",{"name":42,"class":43},"Aron Research Foundation Ets","OTHER",""]